If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Amgen (AMGN) . This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat.This world's largest biotech drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarter ...

With a market cap of $158.6 billion, Amgen Inc. (AMGN) is a leading global biotechnology company headquartered in Thousand Oaks, California. Founded in 1980, Amgen focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics for serious illnesses, with a strong emphasis on oncology, nephrology, cardiovascular disease, and inflammation. The company is expected to release its fiscal Q3 2025 earnings results after the market closes on Tuesday, Nov. 4. Ahead of this event, a ...

Core Insights - Drugmakers are increasingly adopting telehealth platforms for direct-to-consumer sales, aligning with the Trump administration's push for lower drug prices [2][3][5] - Amgen has announced a significant price reduction for its cholesterol-lowering drug Repatha, offering it at a cash price 60% lower than its current list price [2] - The Trump administration is promoting a "most favored nation" policy to tie U.S. drug prices to lower prices abroad, urging companies to implement direct-to-consumer sales models [3] Group 1: Industry Trends - The pharmaceutical industry is moving towards direct-to-consumer sales, allowing patients to purchase medications directly from manufacturers at discounted prices [5] - This shift enables drugmakers to bypass intermediaries like pharmacy benefit managers, potentially increasing their revenue [5] Group 2: Government Initiatives - The Trump administration plans to launch a website, TrumpRx.gov, to facilitate direct online purchases of branded drugs at discounts, with Pfizer agreeing to offer discounts averaging 50% and up to 85% on certain drugs [4] - In July, Trump sent letters to 17 drugmakers, urging them to adopt measures to reduce costs for patients, including direct-to-consumer sales [3]

Core Insights - Amgen has launched a direct-to-consumer program called AmgenNow, offering significant discounts on its drugs, starting with Repatha, which is priced at $239 per month, representing a nearly 60% discount from its U.S. list price [1][8] - The direct-to-patient price for Repatha is the lowest among G-7 advanced economies, targeting uninsured patients and those on high-deductible health plans [2] - Amgen has partnered with GoodRx to provide Repatha at the same price across 70,000 pharmacies nationwide [3] Financial Performance - Repatha has shown strong sales growth since its launch in 2015, with $696 million in sales during Q2 2025, a 31% increase year over year [4] - The company anticipates that Repatha will evolve into a multi-billion-dollar franchise by 2030 [4] Strategic Initiatives - The launch of AmgenNow aligns with political pressures for pharmaceutical companies to reduce drug prices and improve domestic operations [3][9] - Amgen has made significant investments in U.S. manufacturing, including a $650 million investment to expand its network, a $600 million science and innovation center in California, a $900 million manufacturing expansion in Ohio, and a $1 billion facility in North Carolina [10] Industry Context - Amgen's actions may reflect a broader industry trend, following Pfizer's recent agreement with the Trump administration to align drug prices with those in other developed nations [11][12] - The developments from both Amgen and Pfizer could signal a turning point in easing regulatory and pricing pressures in the pharmaceutical industry [12] Stock Performance - Year-to-date, Amgen's shares have increased by 13%, outperforming the industry average growth of 8% [6]

Amgen slashed the price of its cholesterol medication by more than half for U.S. patients through a new medication-access program amid the Trump administration’s call to lower drug prices https://t.co/uBpsJV8KOE ...

Core Insights - Amgen has launched its cholesterol medication, Repatha, directly to consumers in the U.S. at a reduced cash price [2] - This initiative is part of a broader response from pharmaceutical companies to political pressure [2] Company Actions - The launch of Repatha directly to consumers indicates a shift in Amgen's marketing strategy [2] - The reduced cash price aims to make the medication more accessible to patients [2] Industry Context - The move reflects a trend among pharmaceutical companies to address public and political concerns regarding drug pricing [2] - This action may influence competitive dynamics within the cholesterol medication market [2]

Group 1 - The biotechnology company has launched a new direct-to-patient program called AmgenNow, which initially focuses on its drug Repatha [1]

Amgen joins drugmakers offering discounts to cash-paying patients after Trump’s call to cut prices https://t.co/OtfyomPkAP ...

Core Insights - Amgen has initiated direct-to-consumer sales of its cholesterol medication Repatha in the U.S. at a discounted cash price, responding to political pressure regarding drug pricing [1] Group 1: Company Actions - The launch of Repatha for direct consumer sales marks a strategic move by Amgen to enhance accessibility and affordability of its medication [1] - The discounted cash price indicates Amgen's effort to align with ongoing discussions about drug pricing reform in the U.S. [1] Group 2: Industry Context - Amgen's decision reflects a broader trend among pharmaceutical companies to adapt to political and public pressure regarding high drug prices [1] - The move may influence competitive dynamics within the cholesterol medication market, as other companies may need to respond similarly to maintain market share [1]

"Amgen is committed to finding new ways to help patients benefit from our medicines," said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen. "Repatha has already helped more than 5 million patients, and the AmgenNow program will make it easier for uninsured patients or those who choose to pay out-of-pocket to access treatment. This will allow even more Americans at increased risk of major adverse cardiovascular events to benefit from this effective medicine." Beginning today ...